Qin C Ji

Dr. Qin C Ji


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2022 in Bioanalysis
Verified
Journal Article
Closed access
XQXiazi I Qiu
Xiazi I Qiu
JSJohn P Savaryn
John P Savaryn
KRKenneth J Ruterbories
Kenneth J Ruterbories
QJQin C Ji
Qin C Ji
GJGary Jenkins
Gary Jenkins
Background: Currently, no regulatory guidelines are available for parallelism assessment for LC-MS biomarker quantification. Spike recovery, standard addition and dilutional linearity are recommend...

Verified
Journal Article
Open access
PDF file
SLSarah May Lloyd
Sarah May Lloyd
ESElizabeth Sande
Elizabeth Sande
KRKenneth J Ruterbories
Kenneth J Ruterbories
SOStephen O'Brien
Stephen O'Brien
YWYue-Ting Wang
Yue-Ting Wang
QJQin C Ji
Qin C Ji
Alterations to post-translational crosslinking modifications in the extracellular matrix (ECM) are known to drive the pathogenesis of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Thus, the methodology for measuring crosslinking dynamics is valuable for understanding disease progression. The existing crosslinking analysis sample preparation and liquid chromatography tandem mass spectrometry (LC-MS/MS) methods are typically labor-intensive and time-consuming which limits throughput. We, therefore, developed a rapid approach minimizing specialized equipment and hands-on time. The LC-MS/MS sample analysis time was reduced to two minutes per sample. We then improved the analytical integrity of the method by developing a novel surrogate matrix approach for the dihydroxylysinonorleucine (DHLNL) crosslink. By modifying sample preparation, we prepared a tissue-based surrogate matrix with undetectable levels of endogenous DHLNL, providing a strategy for quantifying this crosslink with a more relevant standard matrix. We then applied this rapid methodology to evaluating crosslinking in lung fibrosis. We showed an increase in DHLNL in human IPF lung relative to healthy donors, as well as in a fibrotic mouse model. Finally, we demonstrated that this increase in DHLNL could be mitigated with an anti-fibrotic compound, suggesting that this assay has potential for evaluating pharmaceutical compound efficacy.

1 August 2021 in Journal of Chromatography B
Verified
Journal Article
Closed access
JSJohn Paul Savaryn
John Paul Savaryn
XQXiazi Qiu
Xiazi Qiu
DDDavid B. Duignan
David B. Duignan
CGChristian Goess
Christian Goess
SOSami Osman
Sami Osman
GJGary Jenkins
Gary Jenkins

26 November 2024 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SKSoumya Kandi
Soumya Kandi
SPSarah Blink Polakow
Sarah Blink Polakow
JSJohn P. Savaryn
John P. Savaryn
KRKenneth Ruterbories
Kenneth Ruterbories
MSMary Saltarelli
Mary Saltarelli
QJQin C Ji
Qin C Ji


15 September 2026 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
FJFeng Jin
Feng Jin
CWCraig Wallace
Craig Wallace
WHWilliam Housley
William Housley
MCMarlon Cowart
Marlon Cowart
LELucia Eaton
Lucia Eaton
QJQin C Ji
Qin C Ji